Global Multiple Myeloma Drugs market is expected to grow from US$ 966 million in 2025 to US$ 1404 million in 2031; it is expected to grow at a CAGR of 6.4% from 2025 to 2031.

Global Multiple Myeloma Drugs Market Size and Outlook 2025-31

The global Multiple Myeloma Drugs market size is predicted to grow from US$ 966 million in 2025 to US$ 1404 million in 2031; it is expected to grow at a CAGR of 6.4% from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. Multiple myeloma drugs fall into various drug classes, including proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), alkylating agents, corticosteriods, histone deactylase inhibitors (HDACs), bisphophonates, and monoclonal antibodies (MAbs). The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. Infinity Market Research newest research report, the Multiple Myeloma Drugs Industry Forecast looks at past sales and reviews total world Multiple Myeloma Drugs sales in 2024, providing a comprehensive analysis by region and market sector of projected Multiple Myeloma Drugs sales for 2025 through 2031. With Multiple Myeloma Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Multiple Myeloma Drugs industry. This Insight Report provides a comprehensive analysis of the global Multiple Myeloma Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Multiple Myeloma Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Multiple Myeloma Drugs market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Multiple Myeloma Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Multiple Myeloma Drugs. This report presents a comprehensive overview, market shares, and growth opportunities of Multiple Myeloma Drugs market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; Chemotherapy &nbsp;&nbsp;&nbsp; Corticosteroids &nbsp;&nbsp;&nbsp; Immunomodulators &nbsp;&nbsp;&nbsp; Monoclonal Antibodies &nbsp;&nbsp;&nbsp; Histone Deacetylase (HDAC) Inhibitors &nbsp;&nbsp;&nbsp; Proteasome Inhibitors &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Men &nbsp;&nbsp;&nbsp; Women This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Amgen &nbsp;&nbsp;&nbsp; Johnson & Johnson &nbsp;&nbsp;&nbsp; Celgene &nbsp;&nbsp;&nbsp; Takeda Pharmaceutical &nbsp;&nbsp;&nbsp; Novartis &nbsp;&nbsp;&nbsp; Daiichi Sankyo &nbsp;&nbsp;&nbsp; Merck &nbsp;&nbsp;&nbsp; AB Science &nbsp;&nbsp;&nbsp; Teva &nbsp;&nbsp;&nbsp; PharmaMar Key Questions Addressed in this Report What is the 10-year outlook for the global Multiple Myeloma Drugs market? What factors are driving Multiple Myeloma Drugs market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Multiple Myeloma Drugs market opportunities vary by end market size? How does Multiple Myeloma Drugs break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Multiple Myeloma Drugs Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Multiple Myeloma Drugs by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Multiple Myeloma Drugs by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Multiple Myeloma Drugs Segment by Type &nbsp;2.2.1 Chemotherapy &nbsp;2.2.2 Corticosteroids &nbsp;2.2.3 Immunomodulators &nbsp;2.2.4 Monoclonal Antibodies &nbsp;2.2.5 Histone Deacetylase (HDAC) Inhibitors &nbsp;2.2.6 Proteasome Inhibitors &nbsp;2.2.7 Others &nbsp;2.3 Multiple Myeloma Drugs Sales by Type &nbsp;2.3.1 Global Multiple Myeloma Drugs Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Multiple Myeloma Drugs Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Multiple Myeloma Drugs Sale Price by Type (2020-2025) &nbsp;2.4 Multiple Myeloma Drugs Segment by Application &nbsp;2.4.1 Men &nbsp;2.4.2 Women &nbsp;2.5 Multiple Myeloma Drugs Sales by Application &nbsp;2.5.1 Global Multiple Myeloma Drugs Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Multiple Myeloma Drugs Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Multiple Myeloma Drugs Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Multiple Myeloma Drugs Breakdown Data by Company &nbsp;3.1.1 Global Multiple Myeloma Drugs Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Multiple Myeloma Drugs Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Multiple Myeloma Drugs Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Multiple Myeloma Drugs Revenue by Company (2020-2025) &nbsp;3.2.2 Global Multiple Myeloma Drugs Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Multiple Myeloma Drugs Sale Price by Company &nbsp;3.4 Key Manufacturers Multiple Myeloma Drugs Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Multiple Myeloma Drugs Product Location Distribution &nbsp;3.4.2 Players Multiple Myeloma Drugs Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Multiple Myeloma Drugs by Geographic Region &nbsp;4.1 World Historic Multiple Myeloma Drugs Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Multiple Myeloma Drugs Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Multiple Myeloma Drugs Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Multiple Myeloma Drugs Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Multiple Myeloma Drugs Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Multiple Myeloma Drugs Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Multiple Myeloma Drugs Sales Growth &nbsp;4.4 APAC Multiple Myeloma Drugs Sales Growth &nbsp;4.5 Europe Multiple Myeloma Drugs Sales Growth &nbsp;4.6 Middle East & Africa Multiple Myeloma Drugs Sales Growth 5 Americas &nbsp;5.1 Americas Multiple Myeloma Drugs Sales by Country &nbsp;5.1.1 Americas Multiple Myeloma Drugs Sales by Country (2020-2025) &nbsp;5.1.2 Americas Multiple Myeloma Drugs Revenue by Country (2020-2025) &nbsp;5.2 Americas Multiple Myeloma Drugs Sales by Type (2020-2025) &nbsp;5.3 Americas Multiple Myeloma Drugs Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Multiple Myeloma Drugs Sales by Region &nbsp;6.1.1 APAC Multiple Myeloma Drugs Sales by Region (2020-2025) &nbsp;6.1.2 APAC Multiple Myeloma Drugs Revenue by Region (2020-2025) &nbsp;6.2 APAC Multiple Myeloma Drugs Sales by Type (2020-2025) &nbsp;6.3 APAC Multiple Myeloma Drugs Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Multiple Myeloma Drugs by Country &nbsp;7.1.1 Europe Multiple Myeloma Drugs Sales by Country (2020-2025) &nbsp;7.1.2 Europe Multiple Myeloma Drugs Revenue by Country (2020-2025) &nbsp;7.2 Europe Multiple Myeloma Drugs Sales by Type (2020-2025) &nbsp;7.3 Europe Multiple Myeloma Drugs Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Multiple Myeloma Drugs by Country &nbsp;8.1.1 Middle East & Africa Multiple Myeloma Drugs Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Multiple Myeloma Drugs Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Multiple Myeloma Drugs Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Multiple Myeloma Drugs Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Multiple Myeloma Drugs &nbsp;10.3 Manufacturing Process Analysis of Multiple Myeloma Drugs &nbsp;10.4 Industry Chain Structure of Multiple Myeloma Drugs 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Multiple Myeloma Drugs Distributors &nbsp;11.3 Multiple Myeloma Drugs Customer 12 World Forecast Review for Multiple Myeloma Drugs by Geographic Region &nbsp;12.1 Global Multiple Myeloma Drugs Market Size Forecast by Region &nbsp;12.1.1 Global Multiple Myeloma Drugs Forecast by Region (2026-2031) &nbsp;12.1.2 Global Multiple Myeloma Drugs Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Multiple Myeloma Drugs Forecast by Type (2026-2031) &nbsp;12.7 Global Multiple Myeloma Drugs Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Amgen &nbsp;13.1.1 Amgen Company Information &nbsp;13.1.2 Amgen Multiple Myeloma Drugs Product Portfolios and Specifications &nbsp;13.1.3 Amgen Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Amgen Main Business Overview &nbsp;13.1.5 Amgen Latest Developments &nbsp;13.2 Johnson & Johnson &nbsp;13.2.1 Johnson & Johnson Company Information &nbsp;13.2.2 Johnson & Johnson Multiple Myeloma Drugs Product Portfolios and Specifications &nbsp;13.2.3 Johnson & Johnson Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Johnson & Johnson Main Business Overview &nbsp;13.2.5 Johnson & Johnson Latest Developments &nbsp;13.3 Celgene &nbsp;13.3.1 Celgene Company Information &nbsp;13.3.2 Celgene Multiple Myeloma Drugs Product Portfolios and Specifications &nbsp;13.3.3 Celgene Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Celgene Main Business Overview &nbsp;13.3.5 Celgene Latest Developments &nbsp;13.4 Takeda Pharmaceutical &nbsp;13.4.1 Takeda Pharmaceutical Company Information &nbsp;13.4.2 Takeda Pharmaceutical Multiple Myeloma Drugs Product Portfolios and Specifications &nbsp;13.4.3 Takeda Pharmaceutical Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Takeda Pharmaceutical Main Business Overview &nbsp;13.4.5 Takeda Pharmaceutical Latest Developments &nbsp;13.5 Novartis &nbsp;13.5.1 Novartis Company Information &nbsp;13.5.2 Novartis Multiple Myeloma Drugs Product Portfolios and Specifications &nbsp;13.5.3 Novartis Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Novartis Main Business Overview &nbsp;13.5.5 Novartis Latest Developments &nbsp;13.6 Daiichi Sankyo &nbsp;13.6.1 Daiichi Sankyo Company Information &nbsp;13.6.2 Daiichi Sankyo Multiple Myeloma Drugs Product Portfolios and Specifications &nbsp;13.6.3 Daiichi Sankyo Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Daiichi Sankyo Main Business Overview &nbsp;13.6.5 Daiichi Sankyo Latest Developments &nbsp;13.7 Merck &nbsp;13.7.1 Merck Company Information &nbsp;13.7.2 Merck Multiple Myeloma Drugs Product Portfolios and Specifications &nbsp;13.7.3 Merck Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Merck Main Business Overview &nbsp;13.7.5 Merck Latest Developments &nbsp;13.8 AB Science &nbsp;13.8.1 AB Science Company Information &nbsp;13.8.2 AB Science Multiple Myeloma Drugs Product Portfolios and Specifications &nbsp;13.8.3 AB Science Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 AB Science Main Business Overview &nbsp;13.8.5 AB Science Latest Developments &nbsp;13.9 Teva &nbsp;13.9.1 Teva Company Information &nbsp;13.9.2 Teva Multiple Myeloma Drugs Product Portfolios and Specifications &nbsp;13.9.3 Teva Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Teva Main Business Overview &nbsp;13.9.5 Teva Latest Developments &nbsp;13.10 PharmaMar &nbsp;13.10.1 PharmaMar Company Information &nbsp;13.10.2 PharmaMar Multiple Myeloma Drugs Product Portfolios and Specifications &nbsp;13.10.3 PharmaMar Multiple Myeloma Drugs Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 PharmaMar Main Business Overview &nbsp;13.10.5 PharmaMar Latest Developments 14 Research Findings and Conclusion

Report	Global Multiple Myeloma Drugs Market Growth 2025-2031
Selected License	Multi ID: LPI24975

Buyer Information

Order Summary